Icon (ICLR) Capital Expenditures (2009 - 2026)
Icon's (ICLR) quarterly Capital Expenditures came in at -$42.4 million in Q2 2026, down 31.43% year-over-year from -$61.9 million in Q2 2025, and down 37.86% quarter-over-quarter from -$30.8 million in Q1 2026.
Analysis
Icon (ICLR) Capital Expenditures (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Capital Expenditures for 18 consecutive years, with -$42.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Capital Expenditures fell 31.43% year-over-year to -$42.4 million in Q2 2026; TTM through Jun 2026 was -$81.8 million, a 49.95% decrease from a year earlier, with the FY2025 full-year figure at -$69.8 million, down 22.86% from the prior year.
- Capital Expenditures was -$42.4 million for Q2 2026 at Icon, down from -$30.8 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $50.0 million in Q4 2024 and troughed at -$57.0 million in Q4 2022.
- A 5-year average of -$26.8 million and a median of -$31.5 million in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 125.55% in 2022 and soared 194.79% in 2024, its largest moves.
- Over 5 years, Capital Expenditures stood at -$57.0 million in 2022, then climbed by 7.55% to -$52.7 million in 2023, then surged by 194.79% to $50.0 million in 2024, then decreased by 9.75% to $45.1 million in 2025, then sank by 194.07% to -$42.4 million in 2026.
- The last three Capital Expenditures figures came in at -$42.4 million (Q2 2026), -$30.8 million (Q1 2026), and $45.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 198.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 23.91 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -42.42 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 31.11 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 9.00 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 2.62 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 125,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -55,941.69 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | 23,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.42 Mn |
| Mar 31, 2026 | -30.77 Mn |
| Dec 31, 2025 | 45.10 Mn |
| Sep 30, 2025 | -53.70 Mn |
| Jun 30, 2025 | -32.28 Mn |
| Mar 31, 2025 | -28.91 Mn |
| Dec 31, 2024 | 49.97 Mn |
| Sep 30, 2024 | -43.33 Mn |
| Jun 30, 2024 | -36.29 Mn |
| Mar 31, 2024 | -27.15 Mn |
| Dec 31, 2023 | -52.71 Mn |
| Sep 30, 2023 | -29.10 Mn |
| Jun 30, 2023 | -32.14 Mn |
| Mar 31, 2023 | -26.74 Mn |
| Dec 31, 2022 | -57.02 Mn |
| Sep 30, 2022 | -37.31 Mn |
| Jun 30, 2022 | -28.21 Mn |
| Mar 31, 2022 | -19.63 Mn |
| Dec 31, 2021 | -47.68 Mn |
| Sep 30, 2021 | -24.41 Mn |